Terms: = Sarcomas AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Prognosis
5 results:
1. Development of a novel six DNA damage response-related prognostic signature in osteosarcoma.
Li T; Tang Z; Li S; Lu M
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):110-115. PubMed ID: 38650147
[TBL] [Abstract] [Full Text] [Related]
2. her4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.
Li X; Huang Q; Wang S; Huang Z; Yu F; Lin J
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):345-362. PubMed ID: 32181480
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.
Huang Z; Wang SL; Chen H; Shen RK; Li XD; Huang QS; Wu CY; Weng DF; Lin JH
Scand J Clin Lab Invest; 2019 Dec; 79(8):601-612. PubMed ID: 31663373
[TBL] [Abstract] [Full Text] [Related]
4. [SMARCA4-deficient primary thoracic sarcoma:a clinicopathological analysis of five cases].
Zheng MJ; Zheng Q; Wang Y; Shen L; Zhu XZ; Li Y
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):537-542. PubMed ID: 31288309
[No Abstract] [Full Text] [Related]
5. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract] [Full Text] [Related]
